TAILIEUCHUNG - Báo cáo y học: " Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study"

Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study | López-Cortés et al. AIDS Research and Therapy 2010 7 5 http content 7 1 5 AIDS RESEARCH AND THERAPY RESEARCH Open Access Efficacy safety and pharmacokinetic of once-daily boosted saquinavir 1500 100 mg together with 2 nucleos t ide reverse transcriptase inhibitors in real life a multicentre prospective study Luis F Lopez-Cortes 1 Pompeyo Viciana1 Rosa Ruiz-Valderas1 Juan Pasquau2 Josefa Ruiz3 Fernando Lozano4 Inroc K iorinr i5 A Varmra6 A IKarfr i TcirrAr i7 I I lie .Dr ị-7 ỉì I Cl 7 8 A Dix orr 9 Art ll ici ir 1 I li Srt i z-QTi n 710 Doioies Meiino Antonio Veigaia Albeito leiion Luis Gonzalez Antonio Riveio Agustin Munoz Sanz Abstract Background Ritonavii-boosted saquinavii SQVi is nowadays iegaided as an alternative antiretroviral diug probably due to several drawbacks such as its high pill buiden twice daily dosing and the requirement of 200 mg iitonavii when given at the cuiient standaid 1000 100 mg bid dosing. Several once-daily SQVi dosing schemes have been studied with the 200 mg SQV old foimulations tiying to overcome some of these disadvantages. SQV 500 mg stiength tablets became available at the end of 2005 thus facilitating a once-daily iegimen with fewei pills although there is veiy limited experience with this foimulation yet. Methods Prospective multicentre study in which efficacy safety and phaimacokinetics of a regimen of once-daily SQVi 1500 100 mg plus 2 NRTIs were evaluated undei routine clinical caie conditions in eithei antiretroviral-naive patients oi in those with no pievious histoiy of antiietioviial tieatments and oi genotypic iesistance tests suggesting SQV resistance. Plasma SQV trough levels weie measured by HPLV-UV. Results Five hundred and fourteen caucasian patients weie included coinfected with hepatitis C and oi B viius with ciiihosis . Efficacy at 52 weeks plasma RNA-HIV 50 copies ml was CI95 - by intention-to-tieat and CI95 - by on-tieatment analysis. The reasons foi .

TỪ KHÓA LIÊN QUAN
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.